Kestra Medical Technologies (NASDAQ:KMTS) CFO Vaseem Mahboob Sells 6,995 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) CFO Vaseem Mahboob sold 6,995 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $24.68, for a total transaction of $172,636.60. Following the completion of the sale, the chief financial officer owned 86,896 shares of the company’s stock, valued at approximately $2,144,593.28. The trade was a 7.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Vaseem Mahboob also recently made the following trade(s):

• On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $23.80, for a total transaction of $128,305.80.
• On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.61, for a total transaction of $199,352.37.
• On Thursday, July 30th, Vaseem Mahboob sold 3,980 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.75, for a total transaction of $90,545.00.

Kestra Medical Technologies Stock Performance

NASDAQ KMTS opened at $25.27 on Friday. The company has a 50-day simple moving average of $22.86 and a two-hundred day simple moving average of $22.54. Kestra Medical Technologies, Ltd. has a 12-month low of $14.10 and a 12-month high of $30.00. The firm has a market cap of $1.48 billion, a price-to-earnings ratio of -10.44 and a beta of 0.58. The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16.

Kestra Medical Technologies (NASDAQ:KMTS) last released its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The company had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. On average, equities analysts forecast that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Institutional Trading of Kestra Medical Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of KMTS. Price T Rowe Associates Inc. MD grew its holdings in Kestra Medical Technologies by 137.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock worth $115,878,000 after purchasing an additional 2,529,851 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Kestra Medical Technologies by 180.8% during the fourth quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock valued at $25,221,000 after purchasing an additional 612,343 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Kestra Medical Technologies in the 1st quarter worth approximately $11,036,000. Brown Advisory Inc. boosted its position in shares of Kestra Medical Technologies by 34.1% in the 4th quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock worth $44,775,000 after purchasing an additional 428,996 shares in the last quarter. Finally, Summit Partners Public Asset Management LLC purchased a new stake in shares of Kestra Medical Technologies in the 4th quarter worth approximately $9,282,000.

Analyst Ratings Changes

A number of research analysts have commented on KMTS shares. Oppenheimer initiated coverage on Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a “market perform” rating for the company. Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a report on Wednesday, July 15th. The Goldman Sachs Group cut their price target on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. Wall Street Zen downgraded shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Finally, Weiss Ratings lowered shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 16th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $27.83.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.